Pip Nicolson: Understanding VITT From COVID-19 Vaccines
Pip Nicolson, Associate Clinical Professor in Cardiovascular Medicine (Haematology) at University of Birmingham, shared an insightful thread on X:
“Pleased to be able to share the VITT consortium’s comprehensive final report which sheds light on rare blood clotting syndrome linked to COVID-19 vaccines.
Main Findings:
- The development of antibodies to a small protein released by platelets called Platelet Factor 4 (PF4), which is a key feature of VITT, was probably due to an interaction between the negatively charged “hexon” proteins in the adenoviral vaccine and the positively charged PF4.
- Antibodies to the PF4 protein are uncommon in healthy individuals, vaccinated individuals, and those infected with COVID-19. By contrast, the levels are very high in patients with VITT.
- Whole genome sequencing revealed no significant genetic variants predisposing individuals to VITT, though further RNA sequencing studies are ongoing.
- A strong immune response is seen in patients with VITT – the formation of neutrophil extracellular traps (these are like sticky spider webs formed by white blood cells) and inflammatory reactions, collectively contributed to clot formation.
- The consortium recommends establishing a national reference laboratory registry to improve diagnosis and tracking of Thrombotic Thrombocytopenia Syndrome.
- The findings suggest that future adenoviral vector-based vaccines could be modified to reduce interactions with PF4 and minimise the risk of immune-related complications.
Funded by: NIHR (National Institute of Health and Care Research)
Many Contributors: Prof Cheng-Hock Toh CBE, Richard Buka, Sam Montague, British Society of Haematology, President of British Pharmacological Society Professor Sir Munir Pirmohamed, The Birmingham Platelet Group, Cardiovascular Sciences University of Birmingham, University of Liverpool, Cambridge University”
Read the full VITT Consortium report here.
Article: Understanding mechanisms of thrombosis and thrombocytopenia with adenoviral SARS-CoV-2 vaccines: a comprehensive synopsis
Authors: Phillip LR Nicolson, Simon T Abrams, Gayatri Amirthalingam, Kevin Brown, Richard J Buka, Mark J Caulfield, Joshua Gardner, David Goldblatt, Charlotte Lovatt, Samantha J Montague, Dean J Naisbitt, Alan Parker, Sue Pavord, Mary E Ramsay, Jonathan AC Sterne, Cathie LM Sudlow, Cheng Hock Toh, Steve P Watson, Guozheng Wang, Angela M Wood, William Whiteley, Munir Pirmohamed

Stay updated on the latest scientific advances in the field of thrombotic disorders with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support